Fig. 2

Post-progression survival after first disease progression of any type (a), first nodal relapse (b), and metastatic disease (c). All three genotypes showed similar Kaplan-Meier curves for survival after any disease progression (a) and loco-regional nodal recurrence (b). Patients who were mutant for NRAS showed a slightly shorter median survival in stage IV disease (1.8 years) compared to patients with BRAF mutant (2.2 years) and WT (2.5 years) melanoma. However, this difference was not significant. The indicated p-values were calculated with the log-rank test